The drug registration and marketing authorization application for ferrous succinate tablets from Anhui Zhengyao Pharmaceutical Technology Co., Ltd., a wholly owned subsidiary of Huaren Health, has been accepted by the National Medical Products Administration. This anti-anemia drug is used for the treatment and prevention of iron deficiency anemia. It is indicated for the treatment of iron deficiency anemia caused by chronic blood loss, insufficient iron intake, malabsorption, and other reasons in adults and children, and is also suitable for the prevention of iron deficiency anemia in adults, pregnant women, and children.
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl AMarketing authorization application accepted for ferrous succinate tablets, a new drug approval milestone.
